Skip to main
SNDX

Syndax Pharmaceuticals (SNDX) Stock Forecast & Price Target

Syndax Pharmaceuticals (SNDX) Analyst Ratings

Based on 11 analyst ratings
Strong Buy
Strong Buy 73%
Buy 27%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Syndax Pharmaceuticals is well-positioned for future success with a strong pipeline of combination therapies in multiple cancer indications. Additionally, the company's financials are promising, with a steady increase in revenue and a solid cash flow. As the biopharmaceutical industry continues to grow, Syndax is primed to capitalize and potentially become a leader in the space.

Bears say

Syndax Pharmaceuticals is a clinical-stage biopharmaceutical company with a promising pipeline of combination cancer therapies. However, the company faces several challenges including a potentially limited market for its products, competition from other larger companies, and the need for additional funding. The success of Syndax's products will ultimately depend on its real-world efficacy and its ability to secure a strong market position in the highly competitive field of cancer therapy. Investors should closely monitor the company's progress in clinical trials and its financial situation to assess its potential for long-term success.

Syndax Pharmaceuticals (SNDX) has been analyzed by 11 analysts, with a consensus rating of Strong Buy. 73% of analysts recommend a Strong Buy, 27% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Syndax Pharmaceuticals and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Syndax Pharmaceuticals (SNDX) Forecast

Analysts have given Syndax Pharmaceuticals (SNDX) a Strong Buy based on their latest research and market trends.

According to 11 analysts, Syndax Pharmaceuticals (SNDX) has a Strong Buy consensus rating as of Jul 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $42.45, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $42.45, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Syndax Pharmaceuticals (SNDX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.